Structural studies of the tethered N-terminus of the alzheimer's disease amyloid-β peptide

Proteins: Structure, Function and Bioinformatics

Volumn 81, Issue 10, 2013, Pages 1748-1758

  Nisbet, Rebecca M ^a   Nuttall, Stewart D ^a   Robert, Remy ^a,b   Caine, Joanne M ^a   Dolezal, Olan ^a   Hattarki, Meghan ^a   Pearce, Lesley A ^a   Davydova, Natalia ^a   Masters, Colin L ^c   Varghese, Jose N ^a   Streltsov, Victor A ^a  

^a CSIRO   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

A crystal structure; Alzheimer's disease; Amyloid ; Im7; WO 2 Fab

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; BACTERIAL PROTEIN; COPPER; IMMUNITY PROTEIN 7; IRON; METAL ION; MONOMER; UNCLASSIFIED DRUG; WO2 ANTIBODY; ZINC;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; ESCHERICHIA COLI; METAL BINDING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE;

ESCHERICHIA COLI;

ALZHEIMER'S DISEASE; AMYLOID-Β; AΒ CRYSTAL STRUCTURE; IM7; WO-2 FAB;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS;

EID: 84884202773     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24312     Document Type: Article

References (69)

1. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-842.
2. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
3. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer's b-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002;99:16742-16747.
4. Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, Picone D. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 2002;269:5642-5648.
5. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 1998;37:11064-11077.
6. Shao H, Jao S, Ma K, Zagorski MG. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J Mol Biol 1999;285:755-773.
7. Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, Frank RW, Rosch P. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur J Biochem 1995;233:293-298.
8. Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 1991;253:179-182.
9. Jarvet J, Damberg P, Danielsson J, Johansson I, Eriksson LEG, Gräslund A. A left-handed 31 helical conformation in the Alzheimer Aβ(12-28) peptide. FEBS Lett 2003;555:371-374.
10. Danielsson J, Andersson A, Jarvet J, Gräslund A. 15N relaxation study of the amyloid β-peptide: structural propensities and persistence length. Magn Reson Chem 2006;44:S114-S121.
11. Eker F, Griebenow K, Schweitzer-Stenner R. Abeta(1-28) fragment of the amyloid peptide predominantly adopts a polyproline II conformation in an acidic solution. Biochemistry 2004;43:6893-6898.
12. Blanch EW, Morozova-Roche LA, Cochran DAE, Doig AJ, Hecht L, Barron LD. Is polyproline II helix the killer conformation? a raman optical activity study of the amyloidogenic prefibrillar intermediate of human lysozyme. J Mol Biol 2000;301:553-563.
13. Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 2007;104:15659-15664.
14. Miles LA, Wun KS, Crespi GA, Fodero-Tavoletti MT, Galatis D, Bagley CJ, Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW. Amyloid-β-anti-amyloid-β complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol 2008;377:181-192.
15. Miles LA, Crespi GAN, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep 2013;3:1302.
16. Takano K, Endo S, Mukaiyama A, Chon H, Matsumura H, Koga Y, Kanaya S. Structure of amyloid-β fragments in aqueous environments. FEBS J 2006;273:150-158.
17. Streltsov VA, Varghese JN, Masters CL, Nuttall SD. Crystal structure of the amyloid-beta p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci 2011;31:1419-1426.
18. Chak KF, Safo MK, Ku WY, Hsieh SY, Yuan HS. The crystal structure of the immunity protein of colicin E7 suggests a possible colicin-interacting surface. Proc Natl Acad Sci USA 1996;93:6437-6442.
19. Juraja SM, Mulhern TD, Hudson PJ, Hattarki MK, Carmichael JA, Nuttall SD. Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold. Protein Eng Des Sel 2006;19:231-244.
20. Hosse RJ, Tay L, Hattarki MK, Pontes-Braz L, Pearce LA, Nuttall SD, Dolezal O. Kinetic screening of antibody-Im7 conjugates by capture on a colicin E7 DNase domain using optical biosensors. Anal Biochem 2009;385:346-357.
21. Coia G, Ayres A, Lilley GG, Hudson PJ, Irving RA. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. Gene 1997;201:203-209.
22. Nuttall SD, Krishnan UV, Doughty L, Nathanielsz A, Ally N, Pike RN, Hudson PJ, Kortt AA, Irving RA. A naturally occurring NAR variable domain binds the Kgp protease from Porphyromonas gingivalis. FEBS Lett 2002;516:80-86.
23. Minsky A, Summers RG, Knowles JR. Secretion of beta-lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc Natl Acad Sci USA 1986;83:4180-4184.
24. Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, Coley AM, Casey JL, Anders RF, Foley M, Irving RA, Hudson PJ. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004;55:187-197.
25. Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ, Wark KL. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel 2009;22:199-208.
26. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996;271:22908-22914.
27. Gruen LC, Kortt AA, Nice E. Determination of relative binding affinity of influenza virus N9 sialidases with the Fab fragment of monoclonal antibody NC41 using biosensor technology. Eur J Biochem 1993;217:319-325.
28. McPhillips TM, McPhillips SE, Chiu HJ, Cohen AE, Deacon AM, Ellis PJ, Garman E, Gonzalez A, Sauter NK, Phizackerley RP, Soltis SM, Kuhn P. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat 2002;9:401-406.
29. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-326.
30. Robert R, Streltsov VA, Newman J, Pearce LA, Wark KL, Dolezal O. Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment. Protein Sci 2009;19:299-308.
31. Dennis CA, Videler H, Pauptit RA, Wallis R, James R, Moore GR, Kleanthous C. A structural comparison of the colicin immunity proteins Im7 and Im9 gives new insights into the molecular determinants of immunity-protein specificity. Biochem J 1998;333:183-191.
32. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007;40:658-674.
33. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr 1997;D53:240-255.
34. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010;66:213-221.
35. McRee DE. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J Struct Biol 1999;125:156-165.
36. McRee DE, Badger J. MIFit Manual Version 30 for Windows and LINUX© Rigaku 2003-6.
37. Winn MD, Isupov MN, Murshudov GN. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 2001;57:122-133.
38. Brünger AT. The Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992;355:472-474.
39. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. Overview of the CCP4 suite and current developments. Acta Crystallogr D 2011;67:235-242.
40. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983;22:2577-2637.
41. Frishman D, Argos P. Knowledge-based protein secondary structure assignment. Proteins 1995;23:566-579.
42. Srinivasan R, Rose GD. A physical basis for protein secondary structure. Proc Natl Acad Sci USA 1999;96:14258-14263.
43. Mansiaux Y, Joseph AP, Gelly JC, de Brevern AG. Assignment of PolyProline II conformation and analysis of sequence-structure relationship. PLoS One 2011;6:e18401.
44. Furlan S, Hureau C, Faller P, La Penna G. Modeling the Cu+ binding in the 1-16 region of the amyloid-beta peptide involved in Alzheimer's disease. J Phys Chem B 2010;114:15119-15133.
45. Li S, Hong M. Protonation, tautomerization, and rotameric structure of histidine: a comprehensive study by magic-angle-spinning solid-state NMR. J Am Chem Soc 2011;133:1534-1544.
46. Jha AK, Colubri A, Zaman MH, Koide S, Sosnick TR, Freed KF. Helix, sheet, and polyproline II frequencies and strong nearest neighbor effects in a restricted coil library. Biochemistry 2005;44:9691-9702.
47. Karr JW, Akintoye H, Kaupp LJ, Szalai VA. N-Terminal deletions modify the Cu2+ binding site in amyloid-beta. Biochemistry 2005;44:5478-5487.
48. Stellato F, Menestrina G, Serra MD, Potrich C, Tomazzolli R, Meyer-Klaucke W, Morante S. Metal binding in amyloid beta-peptides shows intra- and inter-peptide coordination modes. Eur Biophys J 2006;35:340-351.
49. Streltsov V, Titmuss S, Epa V, Barnham K, Masters C, Varghese J. The structure of the amyloid-β peptide high-affinity copper II binding site in Alzheimer disease. Biophys J 2008;95:3447-3456.
50. Drew SC, Masters CL, Barnham KJ. Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide-relevance to N-terminally truncated forms. J Am Chem Soc 2009;131:8760-8761.
51. Bousejra-ElGarah F, Bijani C, Coppel Y, Faller P, Hureau C. Iron(II) binding to amyloid-beta, the Alzheimer's peptide. Inorg Chem 2011;50:9024-9030.
52. Yu H, Ren J, Qu X. Different hydration changes accompanying copper and zinc binding to amyloid beta-peptide: water contribution to metal binding. Chembiochem 2008;9:879-882.
53. Tsvetkov PO, Kulikova AA, Golovin AV, Tkachev YV, Archakov AI, Kozin SA, Makarov AA. Minimal Zn(2+) binding site of amyloid-beta. Biophys J 2010;99:L84-L86.
54. Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ. Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J Am Chem Soc 2009;131:1195-1207.
55. Shin BK, Saxena S. Substantial contribution of the two imidazole rings of the His13-His14 dyad to Cu(II) binding in amyloid-beta(1-16) at physiological pH and its significance. J Phys Chem A 2011;115:9590-9602.
56. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205-214.
57. Streltsov VA, Varghese JN. Substrate mediated reduction of copper-amyloid-β complex in Alzheimer's disease. Chem Commun 2008:3169-3171.
58. Atwood CS, Huang X, Khatri A, Scarpa RC, Kim YS, Moir RD, Tanzi RE, Roher AE, Bush AI. Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol (Noisy-le-grand) 2000;46:777-783.
59. Schoneich C. Redox processes of methionine relevant to beta-amyloid oxidation and Alzheimer's disease. Arch Biochem Biophys 2002;397:370-376.
60. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 2003;278:42959-42965.
61. Himes RA, Park GY, Siluvai GS, Blackburn NJ, Karlin KD. Structural studies of copper(I) complexes of amyloid-beta peptide fragments: formation of two-coordinate bis(histidine) complexes. Angew Chem Int Ed Engl 2008;47:9084-9087.
62. Shearer J, Szalai VA. The amyloid-beta peptide of Alzheimer's disease binds Cu(I) in a linear bis-his coordination environment: insight into a possible neuroprotective mechanism for the amyloid-beta peptide. J Am Chem Soc 2008;130:17826-17835.
63. Hureau C, Balland V, Coppel Y, Solari PL, Fonda E, Faller P. Importance of dynamical processes in the coordination chemistry and redox conversion of copper amyloid-beta complexes. J Biol Inorg Chem 2009;14:995-1000.
64. Smith DG, Ciccotosto GD, Tew DJ, Perez K, Curtain CC, Boas JF, Masters CL, Cappai R, Barnham KJ. Histidine 14 modulates membrane binding and neurotoxicity of the Alzheimer's disease amyloid-beta peptide. J Alzheimers Dis 2010;19:1387-1400.
65. Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of AβA21G by neprilysin. Neurobiol Dis 2008;31:442-450.
66. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL, Tew DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL, Cappai R, Barnham KJ. Copper-mediated amyloid-β toxicity is associated with an intermolecular histidine bridge. J Biol Chem 2006;281:15145-15154.
67. Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 2005;280:13355-13363.
68. Barnham KJ, Kenche VB, Ciccotosto GD, Smith DP, Tew DJ, Liu X, Perez K, Cranston GA, Johanssen TJ, Volitakis I, Bush AI, Masters CL, White AR, Smith JP, Cherny RA, Cappai R. Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci USA 2008;105:6813-6818.
69. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 2004;43:560-568.